Mikrodawkowanie psychodelików, potencjalna przyszłość leczenia psychiatrycznego

GBD Results. Institute for Health Metrics and Evaluation. Accessed May 28, 2024. https://vizhub.healthdata.org/gbd-results

Mental Health and COVID-19: Early evidence of the pandemic’s impact: Scientific brief, 2 March 2022. Accessed May 28, 2024. https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Mental_health-2022.1

Anderson T, Petranker R, Christopher A, et al. 3. Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduction Journal. 2019;16(1):43. doi:10.1186/s12954-019-0308-4

Li H, Zhong Y, Yang S, et al. 4. The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta-analysis of randomised controlled trials in healthy volunteers. Hum Psychopharmacol. 2022;37(3):e2825. doi:10.1002/hup.2825

Vann Jones SA, O’Kelly A. 5. Psychedelics as a Treatment for Alzheimer’s Disease Dementia. Front Synaptic Neurosci. 2020;12:34. doi:10.3389/fnsyn.2020.00034

Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives - Ayse Ceren Kaypak, Amir Raz, 2022. Accessed May 28, 2024. https://journals.sagepub.com/doi/10.1177/13634615221119386

Kaypak AC, Raz A. 7. Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives. Transcult Psychiatry. 2022;59(5):665-674. doi:10.1177/13634615221119386

Lowe H, Toyang N, Steele B, et al. 8. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. Molecules. 2022;27(8):2520. doi:10.3390/molecules27082520

Polito V, Liknaitzky P. 9. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. Neurosci Biobehav Rev. 2022;139:104706. doi:10.1016/j.neubiorev.2022.104706

The_International_Drug_Control_Conventions_E.pdf. Accessed May 28, 2024. https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/Ebook/The_International_Drug_Control_Conventions_E.pdf

Polito V, Stevenson RJ. 11. A systematic study of microdosing psychedelics. PLoS One. 2019;14(2):e0211023. doi:10.1371/journal.pone.0211023

Rosenbaum D, Weissman C, Anderson T, et al. 12. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities. J Psychopharmacol. 2020;34(6):612-622. doi:10.1177/0269881120908004

Kuypers KPC. 13. The therapeutic potential of microdosing psychedelics in depression. Ther Adv Psychopharmacol. 2020;10:2045125320950567. doi:10.1177/2045125320950567

Ling S, Ceban F, Lui LMW, et al. 14. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs. 2022;36(1):17-30. doi:10.1007/s40263-021-00877-y

Psiuk D, Nowak EM, Dycha N, Łopuszańska U, Kurzepa J, Samardakiewicz M. 15. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. Int J Mol Sci. 2022;23(19):11450. doi:10.3390/ijms231911450

Goodwin GM, Aaronson ST, Alvarez O, et al. 16. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord. 2023;327:120-127. doi:10.1016/j.jad.2023.01.108

Więckiewicz G, Stokłosa I, Piegza M, Gorczyca P, Pudlo R. 17. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals (Basel). 2021;14(8):793. doi:10.3390/ph14080793

Perez N, Langlest F, Mallet L, et al. 18. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. Eur Neuropsychopharmacol. 2023;76:61-76. doi:10.1016/j.euroneuro.2023.07.011

Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC. 19. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol. 2018;11(9):889-902. doi:10.1080/17512433.2018.1511424

Gasser P, Holstein D, Michel Y, et al. 20. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513-520. doi:10.1097/NMD.0000000000000113

Berman RM, Cappiello A, Anand A, et al. 21. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. doi:10.1016/s0006-3223(99)00230-9

Feifel D, Shilling PD, MacDonald K. 22. A Review of Oxytocin’s Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia. Biol Psychiatry. 2016;79(3):222-233. doi:10.1016/j.biopsych.2015.07.025

Leger RF, Unterwald EM. 23. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. J Psychopharmacol. 2022;36(1):20-30. doi:10.1177/02698811211044688

Romeo B, Karila L, Martelli C, Benyamina A. 24. Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. J Psychopharmacol. 2020;34(10):1079-1085. doi:10.1177/0269881120919957

Zia FZ, Baumann MH, Belouin SJ, et al. 25. Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. Neuropharmacology. 2023;233:109528. doi:10.1016/j.neuropharm.2023.109528

Schindler EAD. 26. Psychedelics in the Treatment of Headache and Chronic Pain Disorders. Curr Top Behav Neurosci. 2022;56:261-285. doi:10.1007/7854_2022_365

Microdosing psilocybin for chronic pain: a case series - PubMed. Accessed May 29, 2024. https://pubmed.ncbi.nlm.nih.gov/36066961/

Kooijman NI, Willegers T, Reuser A, et al. 28. Are psychedelics the answer to chronic pain: A review of current literature. Pain Pract. 2023;23(4):447-458. doi:10.1111/papr.13203

Schindler EAD, Hendricks PS. 29. Adapting psychedelic medicine for headache and chronic pain disorders. Expert Rev Neurother. 2023;23(10):867-882. doi:10.1080/14737175.2023.2246655

Kelmendi B, Kaye AP, Pittenger C, Kwan AC. 30. Psychedelics. Curr Biol. 2022;32(2):R63-R67. doi:10.1016/j.cub.2021.12.009

Pilozzi A, Foster S, Mischoulon D, Fava M, Huang X. 31. A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression. Int J Mol Sci. 2023;24(15):12513. doi:10.3390/ijms241512513

How many people have dementia in the UK? | Alzheimer’s Society. Accessed May 29, 2024. https://www.alzheimers.org.uk/blog/how-many-people-have-dementia-uk

Draper: Understanding Alzheimer’s disease and other... - Google Scholar. Accessed May 29, 2024. https://scholar.google.com/scholar_lookup?title=Understanding+Alzheimer%27s+Disease+and+Other+Dementias&author=Draper+B.&publication_year=2013

Garcia-Romeu A, Darcy S, Jackson H, White T, Rosenberg P. 34. Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms. Curr Top Behav Neurosci. 2022;56:287-317. doi:10.1007/7854_2021_267

Saeger HN, Olson DE. 35. Psychedelic-inspired approaches for treating neurodegenerative disorders. J Neurochem. 2022;162(1):109-127. doi:10.1111/jnc.15544

Winkelman MJ, Szabo A, Frecska E. 36. The potential of psychedelics for the treatment of Alzheimer’s disease and related dementias. Eur Neuropsychopharmacol. 2023;76:3-16. doi:10.1016/j.euroneuro.2023.07.003

McManus KR, Patrick R, Striepe MI, et al. 37. Psychedelics for Alzheimer’s Disease Palliative Care. Adv Psychiatry Behav Health. 2022;2(1):37-46. doi:10.1016/j.ypsc.2022.06.001

Haj ME, Jardri R, Larøi F, Antoine P. 38. Hallucinations, loneliness, and social isolation in Alzheimer’s disease. Cognitive Neuropsychiatry. Published online January 2, 2016. Accessed May 29, 2024. https://www.tandfonline.com/doi/abs/10.1080/13546805.2015.1121139

Social Disengagement and Incident Cognitive Decline in Community-Dwelling Elderly Persons | Annals of Internal Medicine. Accessed May 29, 2024. https://www.acpjournals.org/doi/10.7326/0003-4819-131-3-199908030-00002

Full article: Psychedelics and music: neuroscience and therapeutic implications. Accessed May 29, 2024. https://www.tandfonline.com/doi/full/10.1080/09540261.2018.1484342

Jetten J, Haslam C, Pugliese C, Tonks J, Haslam SA. 41. Declining autobiographical memory and the loss of identity: Effects on well-being. Journal of Clinical and Experimental Neuropsychology. 2010;32(4):408-416. doi:10.1080/13803390903140603

Sinha JK, Trisal A, Ghosh S, et al. 42. Psychedelics for alzheimer’s disease-related dementia: Unveiling therapeutic possibilities and pathways. Ageing Res Rev. 2024;96:102211. doi:10.1016/j.arr.2024.102211

Hayes C, Wahba M, Watson S. 43. Will psilocybin lose its magic in the clinical setting? Ther Adv Psychopharmacol. 2022;12:20451253221090822. doi:10.1177/20451253221090822

Williams ML, Korevaar D, Harvey R, et al. 44. Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead. Front Psychiatry. 2021;12:737738. doi:10.3389/fpsyt.2021.737738

Evans J, Robinson OC, Argyri EK, et al. 45. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS One. 2023;18(10):e0293349. doi:10.1371/journal.pone.0293349

Kirsch I. 46. Placebo Effect in the Treatment of Depression and Anxiety. Front Psychiatry. 2019;10:407. doi:10.3389/fpsyt.2019.00407

Szigeti B, Heifets BD. 47. Expectancy Effects in Psychedelic Trials. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9(5):512-521. doi:10.1016/j.bpsc.2024.02.004

Kious B, Schwartz Z, Lewis B. 48. Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers. J Psychopharmacol. 2023;37(1):45-48. doi:10.1177/02698811221133461

Sicignano D, Snow-Caroti K, Hernandez AV, White CM. 49. The Impact of Psychedelic Drugs on Anxiety and Depression in Advanced Cancer or other Life-threatening Disease: A Systematic Review With Meta-analysis. Am J Clin Oncol. 2023;46(6):236-245. doi:10.1097/COC.0000000000000998

Reiff CM, Richman EE, Nemeroff CB, et al. 50. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. 2020;177(5):391-410. doi:10.1176/appi.ajp.2019.19010035

Majić T, Jungaberle H, Schmidt TT, Zeuch A, Hermle L, Gallinat J. 51. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges]. Fortschr Neurol Psychiatr. 2017;85(7):383-392. doi:10.1055/s-0043-103085

Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. 52. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36(3):258-272. doi:10.1177/02698811211069100

Nutt DJ, King LA, Phillips LD. 53. Drug harms in the UK: a multicriteria decision analysis. The Lancet. 2010;376(9752):1558-1565. doi:10.1016/S0140-6736(10)61462-6

Lowe H, Toyang N, Steele B, et al. 54. The Therapeutic Potential of Psilocybin. Molecules. 2021;26(10):2948. doi:10.3390/molecules26102948

Hall W. 55. Why was early therapeutic research on psychedelic drugs abandoned? Psychol Med. 2022;52(1):26-31. doi:10.1017/S0033291721004207

Friesen P. 56. Psychosis and psychedelics: Historical entanglements and contemporary contrasts. Transcult Psychiatry. 2022;59(5):592-609. doi:10.1177/13634615221129116

Sanders JW, Zijlmans J. 57. Moving Past Mysticism in Psychedelic Science. ACS Pharmacol Transl Sci. 2021;4(3):1253-1255. doi:10.1021/acsptsci.1c00097

Dupuis D, Veissière S. 58. Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos? Transcult Psychiatry. 2022;59(5):571-578. doi:10.1177/13634615221131465

Villiger D, Trachsel M. 59. With great power comes great vulnerability: an ethical analysis of psychedelics’ therapeutic mechanisms proposed by the REBUS hypothesis. J Med Ethics. 2023;49(12):826-832. doi:10.1136/jme-2022-108816

Holoyda B, Kiani C. 60. Establishing an Ethics for Psychedelic Psychiatry. Psychiatr Serv. 2023;74(8):789. doi:10.1176/appi.ps.23074013

Frontiers | Psychedelics as Tools for Belief Transmission. Set, Setting, Suggestibility, and Persuasion in the Ritual Use of Hallucinogens. Accessed May 29, 2024. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2021.730031/full

Barber GS, Dike CC. 62. Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry. Psychiatr Serv. 2023;74(8):838-846. doi:10.1176/appi.ps.20220525